Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
TGR-1202
TG THERAPEUTICS, INC.
Chronic Lymphocytic Leukemia
1 trial -
TGRX-326
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
THIO-101
MAIA Biotechnology
Non-Small Cell Lung Cancer
1 trial -
THOR-707
Sanofi Pasteur
Malignant Melanoma
1 trial -
TISAGENLECLEUCEL
Novartis Pharmaceuticals
High-risk B-cell acute lymphoblastic leukemia
1 trial -
TISAGENLECLEUCEL
Novartis Pharmaceuticals
Adult patients with refractory or relapsed follicular lymphoma
1 trial -
TISLELIZUMAB
Fondazione Telethon ETS
Hodgkin lymphoma
1 trial -
TKM-080301
Arbutus Biopharma Corp
Hepatocellular Carcinoma
1 trial -
TKM-080301
Arbutus Biopharma Corp
Cancer
1 trial -
TL-895, TL-895
Lacuna Pharma Pty Ltd
B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
1 trial -
TNG260
Tango Therapeutics
Non Small Cell Lung Cancer
1 trial -
TNG348
Tango Therapeutics
Breast Cancer
1 trial -
TNG456
Tango Therapeutics
Non Small Cell Lung Cancer
1 trial -
TNG462
Tango Therapeutics
Locally Advanced Solid Tumor
1 trial -
TNG908
Tango Therapeutics
Locally Advanced Solid Tumor
1 trial -
TNG908-C101
Tango Therapeutics
"Ph1: •Locally advanced (LA) or metastatic MTAP-deleted (met.MTAP-del.) solid tumors •MTAP-del.relapsed or refrac. Grade 4 astrocytoma or glioblastoma multiforme (R/R GBM) Ph2: A1:LA or met.MTAP-del. squamous and nonsquamous NSCLC A2:LA or met.MTAP-del. mesothelioma A3:LA or met.MTAP-del. sarcoma A4:LA or met.MTAP-del. pancreatic ductal adenocarcinoma or adenosquamous carcinoma w/predominantly adenocarcinoma histology A5:Other LA or met.MTAP-del. solid tumors A6:MTAP-del. R/R GBM"
1 trial -
TNT-OES-2
Disc Medicine
oesophageal cancer, oesophagogastric junction cancer
1 trial -
TOCILIZUMAB for Mantle Cell Lymphoma
Fondazione Telethon ETS
Mantle Cell Lymphoma
1 trial -
TPC induction chemotherapy
Sun Yat-sen University
Nasopharyngeal Carcinoma
1 trial -
TPIV200
Marker Therapeutics
Ovarian Cancer
1 trial -
TPX-0005-07
Turn Therapeutics
Advanced solid tumors
1 trial -
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Prostatic Neoplasms, Castration-Resistant
1 trial -
TQB3616 capsules
Chia Tai Tianqing Pharmaceutical Group Co.,
HR-positive, HER2-negative Advanced Breast Cancer
1 trial -
TRAP-BTC
The George Institute
cholangiocarcinoma or gallbladder carcinoma
1 trial -
TRASTUZUMAB DERUXTECAN
Fondazione Telethon ETS
metastatic HER2-positive breast cancer patients
1 trial -
TRASTUZUMAB DERUXTECAN, SACITUZUMAB GOVITECAN
Ningbo Cancer Hospital
Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication.
1 trial -
TRC105
United Therapeutics Europe Ltd
Metastatic Breast Cancer
1 trial -
TREMELIMUMAB for locally advanced cholangiocarcinoma
Fondazione Telethon ETS
locally advanced cholangiocarcinoma
1 trial -
TREMELIMUMAB, DURVALUMAB
The George Institute
MSS and MSI colorectal and endometrial tumors
1 trial -
TRU-016 and bendamustine
Aptevo Therapeutics
Chronic Lymphocytic Leukemia (CLL)
1 trial -
TS-1 with cisplatin
Hospital Authority, Hong Kong
Recurrent Gastric Cancer
1 trial -
TTI-101
Tvardi Therapeutics
Head and Neck Squamous Cell Carcinoma
1 trial -
TTI-101
Tvardi Therapeutics
Hepatocellular Carcinoma
1 trial -
TTX-MC138
Transcode Therapeutics
Advanced Solid Tumor
1 trial -
TYR300-101
Tyra Biosciences
Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations
1 trial -
TYR300-202
Tyra Biosciences
Non-muscle invasive bladder cancer (NMIBC)
1 trial -
TYRA-300
Tyra Biosciences
Locally Advanced Urothelial Carcinoma
1 trial -
Tabelecleucel
Evidence Based Cataract Study Group
Nasopharyngeal Carcinoma
1 trial -
Tagraxofusp
Stemline Therapeutics B.V.
Acute Myeloid Leukemia
1 trial -
Tak-228 & Tak-117
Takeda
Triple Negative Breast Cancer
1 trial -
Talazoparib Tosylate
BioMarin Pharmaceutical Australia Pty Ltd
Advanced Breast Cancer
1 trial -
Tarlatamab
Amgen
Relapsed/Refractory Small Cell Lung Cancer
1 trial -
Tarlatamab, Tarlatamab
Partner Therapeutics Limited
Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2
1 trial -
Tarlatamab, Tarlatamab
The George Institute
Metastaic small cell lung cancer (SCLC) and other poorly differentitated neuroendocrine carcinomas (NECs)
1 trial -
Tas-102(Suyuan) combined with bevacizumab
The First People's Hospital of Lianyungang
Colorectal Cancer
1 trial -
Taxotere
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
Tazemetostat
Eisai Co.,
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion
The George Institute
Locally advanced cervical cancer
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.